These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 36065745)

  • 1. Risk of Reactivation of Latent Tuberculosis in Psoriasis Patients on Biologic Therapies: A Retrospective Cohort from a Tertiary Care Centre in Northern Italy.
    Mastorino L; Dapavo P; Trunfio M; Avallone G; Rubatto M; Calcagno A; Ribero S; Quaglino P
    Acta Derm Venereol; 2022 Nov; 102():adv00821. PubMed ID: 36065745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of latent tuberculosis infection in patients with moderate to severe psoriasis taking biologic therapies in a dermatologic private practice in Miami, Florida.
    Medina-Gil C; Dehesa L; Vega A; Kerdel F
    Int J Dermatol; 2015 Jul; 54(7):846-52. PubMed ID: 26108266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis - time for a paradigm change.
    Nogueira M; Warren RB; Torres T
    J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):824-834. PubMed ID: 32790003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study.
    Torres T; Chiricozzi A; Puig L; Lé AM; Marzano AV; Dapavo P; Dauden E; Carrascosa JM; Lazaridou E; Duarte G; Carvalho AVE; Romiti R; Rompoti N; Teixeira L; Abreu M; Ippoliti E; Maronese CA; Llamas-Velasco M; Vilarrasa E; Del Alcázar E; Daponte AI; Papoutsaki M; Carugno A; Bellinato F; Gisondi P
    Am J Clin Dermatol; 2024 Mar; 25(2):333-342. PubMed ID: 38265746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of tuberculosis reactivation during interleukin-17 inhibitor therapy for psoriasis: a systematic review.
    Fowler E; Ghamrawi RI; Ghiam N; Liao W; Wu JJ
    J Eur Acad Dermatol Venereol; 2020 Jul; 34(7):1449-1456. PubMed ID: 32012384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom.
    Nisar MK; Rafiq A; Östör AJ
    Clin Rheumatol; 2015 Dec; 34(12):2141-5. PubMed ID: 26497501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of long-term therapy with biological drugs in psoriatic patients with latent tuberculosis infection in real life setting.
    Conti A; Piaserico S; Gisondi P; Odorici G; Galdo G; Lasagni C; Pellacani G
    Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28547750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual latent tuberculosis screening with tuberculin skin tests and QuantiFERON-TB assays before TNF-α inhibitor initiation in children in Spain.
    Calzada-Hernández J; Anton J; Martín de Carpi J; López-Montesinos B; Calvo I; Donat E; Núñez E; Blasco Alonso J; Mellado MJ; Baquero-Artigao F; Leis R; Vegas-Álvarez AM; Medrano San Ildefonso M; Pinedo-Gago MDC; Eizaguirre FJ; Tagarro A; Camacho-Lovillo M; Pérez-Gorricho B; Gavilán-Martín C; Guillén S; Sevilla-Pérez B; Peña-Quintana L; Mesa-Del-Castillo P; Fortuny C; Tebruegge M; Noguera-Julian A
    Eur J Pediatr; 2023 Jan; 182(1):307-317. PubMed ID: 36335186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents.
    Doherty SD; Van Voorhees A; Lebwohl MG; Korman NJ; Young MS; Hsu S; National Psoriasis Foundation
    J Am Acad Dermatol; 2008 Aug; 59(2):209-17. PubMed ID: 18485527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-γ release assay for tuberculosis in patients with psoriasis treated with tumour necrosis factor antagonists: in vivo and in vitro analysis.
    Sauzullo I; Mengoni F; Marocco R; Potenza C; Skroza N; Tieghi T; Lichtner M; Vullo V; Mastroianni CM
    Br J Dermatol; 2013 Nov; 169(5):1133-40. PubMed ID: 23909256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of QuantiFERON®-TB Gold test in psoriatic patients under treatment with tumour necrosis factor blockers.
    Saraceno R; Specchio F; Chiricozzi A; Sarmati L; Amicosante M; Chimenti MS; Chimenti S
    Expert Opin Biol Ther; 2014 Feb; 14(2):151-6. PubMed ID: 24303977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serial Quantiferon-TB Gold test results in 279 patients with psoriasis receiving biologic therapy.
    Akdogan N; Dogan S; Gulseren D; Yalici-Armagan B; Ersoy-Evans S; Elcin G; Karaduman A; Atakan N
    Dermatol Ther; 2021 Jan; 34(1):e14699. PubMed ID: 33368959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tuberculosis Risk Stratification of Psoriatic Patients Before Anti-TNF-α Treatment.
    Benhadou F; Dirix V; Domont F; Willaert F; Van Praet A; Locht C; Mascart F; Corbière V
    Front Immunol; 2021; 12():672894. PubMed ID: 34149708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rates of latent tuberculosis infection in patients treated with TNF inhibitors for psoriasis: a retrospective chart review.
    Lee EB; Amin M; Man J; Egeberg A; Wu JJ
    J Dermatolog Treat; 2018 Nov; 29(7):671-675. PubMed ID: 29455561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of tuberculosis with anti-tumor necrosis factor-alpha therapy in patients with psoriasis and psoriatic arthritis in Indian population.
    Sarkar S; Panda S; Kim B; Raychaudhuri SK; Ghosh A; Raychaudhuri SP
    Indian J Dermatol Venereol Leprol; 2020; 86(1):1-7. PubMed ID: 31719235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammatory bowel disease and mycobacteria: how much can we trust isoniazid prophylaxis during antitumor necrosis factor therapy?
    Akyuz F; Cavus B; Iliaz R; Soyer OM; Ormeci A; Evirgen S; Onder S; Koksalan K; Keskin M; Karaca C; Demir K; Gulluoglu M; Cagatay T; Besisik F; Kaymakoglu S
    Eur J Gastroenterol Hepatol; 2019 Jul; 31(7):777-780. PubMed ID: 30964811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired latent tuberculosis infection in psoriasis patients treated with etanercept in the People's Republic of China.
    Li CR; Mao QX; Chen M; Jia WX; Yao X; Feng SY; Jia H; Gong JQ; Yang XY
    Drug Des Devel Ther; 2015; 9():5591-4. PubMed ID: 26508833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice.
    Cantini F; Nannini C; Niccoli L; Iannone F; Delogu G; Garlaschi G; Sanduzzi A; Matucci A; Prignano F; Conversano M; Goletti D;
    Autoimmun Rev; 2015 Jun; 14(6):503-9. PubMed ID: 25617816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis.
    Elewski BE; Baddley JW; Deodhar AA; Magrey M; Rich PA; Soriano ER; Soung J; Bao W; Keininger D; Marfo K; Patekar M; Sharma A; Shete A; Lebwohl MG
    JAMA Dermatol; 2021 Jan; 157(1):43-51. PubMed ID: 33001147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tuberculosis screening guidelines should be updated and quantiferon test should be a prerequisite prior to the initiation of treatment of psoriasis with biological agents.
    Tamer F; Gulekon A
    Eur Rev Med Pharmacol Sci; 2022 Dec; 26(23):8788-8794. PubMed ID: 36524497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.